Purpose: It is thought that proteoglycan (PG) alterations, collagen matrix reorganisation and the onset of corneal transparency in the developing avian cornea might be related events. The current histochemical study was designed to establish the character and distribution of corneal PG filaments in relation to collagen organisation during tissue morphogenesis. Methods: Corneas from days 13–18 developing chicken embryos were treated with cuprolinic blue (CuB) to examine sulphated PGs by transmission electron microscopy and quantitative image analysis. Results: On developmental day 13, corneas contained poorly defined lamellae and a large number of both small and large CuB-stained PG filaments, randomly distributed and often in collagen-free regions. By day 14 and after, the large CuB-stained PG filaments were much less abundant. At this time, too, collagen fibrils displayed an axial alignment and an occasional periodic arrangement of small CuB-stained PG filaments along their axes. By developmental day 15, lamellae were well formed and continued to increase in number and size thereafter. Between developmental days 16 and 17, there was a significant increase (p < 0.001) in the number of small, collagen-associated PG filaments. This increase persisted into day 18. Conclusions: The size, number and distribution of sulphated, CuB-stained PG filaments in the developing avian cornea change over time. This is particularly true between developmental days 13 and 14 and between days 16 and 17, concurrent with previously documented structural changes.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.